In vitro and in vivo sustained zero-order delivery of Rapamycin (sirolimus) from a biodegradable intraocular device
Lance K.D., Good S.D., Mendes T.S., Ishikiriyama M., Chew P., Estes L.S., Yamada K., Mudumba S., Bhisitkul R.B., Desai T.A.
View publication
-
Technology
Drug Delivery
-
Affiliations
University of California at Berkeley–University of California, San Francisco, CA, United States; Department of Ophthalmology, University of California San Francisco, San Francisco, CA, United States; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, United States; Pharmaceutical Development Group, Pharmaceutical Development Center, Santen Pharmaceutical Co., Ltd, Nara, Japan; Pharmaceutical Development, Santen, Inc, Emeryville, CA, United States